Epidemiology of psoriasis in the Russian Federation according to the patient registry

Cover Page

Cite item

Full Text

Abstract

Background. Psoriasis is a chronic skin disorder that impairs patients’ health-related quality of life. It is associated with patients’ need in specialized medical care and with essential medical costs. Psoriasis may be the reason for temporary or permanent disability. Patient registries are important sources of epidemiological and clinical data on patients with psoriasis and medical care provided.

Aims. To describe demographic characteristics, characteristics of the disease, prevalence of concomitant and past diseases in adult (18 years and older) patients with moderate and severe psoriasis included in the patient registry of the Russian Society of Dermatovenereologists and Cosmetologists.

Materials and methods. The data of 3,268 patients with psoriasis aged 18 years and older were analyzed as of inclusion in the registry. Data lock point was June 3, 2021. Descriptive statistics methods were applied in data analysis.

Results. The mean (± SD) age of adult patients at inclusion in the registry was 46.1 ± 14.4 years. Male patients accounted for 60.5%. The mean age of onset of psoriasis is 31.1 ± 16.1 years. Most of the patients (89.5%) have psoriasis vulgaris. The mean body surface area at inclusion was 43.3% ± 24.7%. 28.9% of patients had psoriatic arthritis at inclusion in the registry.

A high prevalence of cardiovascular diseases was revealed: arterial hypertension — 28.5%, coronary heart disease — 5.4%, myocardial infarction and acute cerebrovascular accident — 0.9% each.

More than half of patients are pre-obese or obese according to the WHO body mass index classification. 2.2% of patients have impaired glucose tolerance, 6.7% of patients have type 2 diabetes mellitus. 3.8% of patients have diseases or dysfunction of the thyroid gland.

The prevalence of diseases of the digestive system is high: any disease of the esophagus, stomach and duodenum was noted in 10.2% of patients, any disease of the liver, gallbladder, biliary tract and pancreas — in 11.8% of patients.

The prevalence of viral hepatitis C among patients with psoriasis was 2.6%.

Conclusions. The prevalence of comorbidities is high among Russian patients with moderate and severe psoriasis.

About the authors

Alexey A. Kubanov

State Research Center of Dermatovenereology and Cosmetology

Email: alex@cnikvi.ru
ORCID iD: 0000-0002-7625-0503
SPIN-code: 8771-4990

MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

Russian Federation, Korolenko str., 3, bldg 6, 107076, Moscow

Elena V. Bogdanova

State Research Center of Dermatovenereology and Cosmetology

Author for correspondence.
Email: bogdanova@cnikvi.ru
ORCID iD: 0000-0002-0662-2682
SPIN-code: 6372-2237

MD, Cand. Sci. (Med.)

Russian Federation, Korolenko str., 3, bldg 6, 107076, Moscow

References

  1. Кубанов А.А., Бакулев А.Л., Карамова А.Э., Притуло О.А., Аршинский М.И., Знаменская Л.Ф. и др. Клинические рекомендации. Псориаз. 2020 г. [Kubanov AA, Bakulev AL, Karamova AE, Pritulo OA, Arshinskij MI, Znamenskaja LF, et al. Klinicheskie rekomendacii. Psoriaz. 2020 (In Russ.)]. https://cr.minzdrav.gov.ru/
  2. Martínez-Ortega JM, Nogueras P, Muñoz-Negro JE, Gutiérrez-Rojas L, González-Domenech P, Gurpegui M. Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study. J Psychosom Res. 2019;124:109780. doi: 10.1016/j.jpsychores.2019.109780
  3. Kelly A, Ryan C. Genital Psoriasis: Impact on Quality of Life and Treatment Options. Am J Clin Dermatol. 2019;20(5):639–646. doi: 10.1007/s40257-019-00447-5
  4. Guo F, Yu Q, Liu Z, Zhang C, Li P, Xu Y, et al. Evaluation of life quality, anxiety, and depression in patients with skin diseases. Medicine (Baltimore). 2020;99(44):e22983. doi: 10.1097/MD.0000000000022983.
  5. Bulat V, Šitum M, Delaš Aždajić M, Lovrić I, Dediol I. Study on the Impact of Psoriasis on Quality of Life: Psychological, Social and Financial Implications. Psychiatr Danub. 2020;32(Suppl 4):553–561
  6. Jankowiak B, Kowalewska B, Krajewska-Kułak E, Khvorik DF. Stigmatization and Quality of Life in Patients with Psoriasis. Dermatol Ther (Heidelb). 2020;10(2):285–296. doi: 10.1007/s13555-020-00363-1
  7. Jankowiak B, Kowalewska B, Krajewska-Kułak E, Kowalczuk K, Khvorik DF. The Sense of Stigmatization in Patients with Plaque Psoriasis. Dermatology. 2021;237(4):611–617. doi: 10.1159/000510654
  8. van Beugen S, van Middendorp H, Ferwerda M, Smit JV, Zeeuwen-Franssen ME, Kroft EB, et al. Predictors of perceived stigmatization in patients with psoriasis. Br J Dermatol. 2017;176(3):687–694. doi: 10.1111/bjd.14875
  9. Orbai AM, Reddy SM, Dennis N, Villacorta R, Peterson S, et al. Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020. Clin Rheumatol. 2021;40(12):4933–4942. doi: 10.1007/s10067-021-05839-9
  10. Murage MJ, Anderson A, Oliveria SA, Casso D, Ojeh CK, Muram TM, et al. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity. J Med Econ. 2018;21(8):745–754. doi: 10.1080/13696998.2018.1472097
  11. Al Sawah S, Foster SA, Goldblum OM, Malatestinic WN, Zhu B, Shi N, et al. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J Med Econ. 2017;20(9):982–990. doi: 10.1080/13696998.2017.1345749
  12. Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, Casado MÁ. The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review. Actas Dermosifiliogr. 2016;107(7):577–590. English, Spanish. doi: 10.1016/j.ad.2016.04.018
  13. Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(5):685–705. doi: 10.1586/14737167.2014.933671
  14. Assessing work-related productivity loss and indirect costs of psoriasis across six countries. Br J Dermatol. 2020;183(3):e65-e90. doi: 10.1111/bjd.19351
  15. Villacorta R, Teeple A, Lee S, Fakharzadeh S, Lucas J, McElligott S. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis. Br J Dermatol. 2020;183(3):548–558. doi: 10.1111/bjd.18798
  16. Body mass index — BMI. https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi
  17. Kimball AB, Leonardi C, Stahle M, Gulliver W, Chevrier M, Fakharzadeh S, et al.; PSOLAR Steering Committee. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014;171(1):137–47. doi: 10.1111/bjd.13013
  18. Iskandar IY, Ashcroft DM, Warren RB, Yiu ZZ, McElhone K, Lunt M, et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br J Dermatol. 2015;173(2):510–518. doi: 10.1111/bjd.13908
  19. Kojanova M, Fialova J, Cetkovska P, Gkalpakiotis S, Jircikova J, Dolezal T, et al; BIOREP study group. Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. Int J Dermatol. 2017;56(4):428–434. doi: 10.1111/ijd.13543
  20. Global report on psoriasis. World Health Organization. — 2016. ISBN 978 92 4 156518 9. https://www.who.int/publications/i/item/global-report-on-psoriasis
  21. Hägg D, Eriksson M, Sundström A, Schmitt-Egenolf M. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS One. 2013;8(5):e63619. doi: 10.1371/journal.pone.0063619
  22. Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol. 2017;18(4):583–590. doi: 10.1007/s40257-017-0274-0
  23. Bożek A, Reich A. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 2017;26(5):851–856. doi: 10.17219/acem/69804
  24. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–112. [Dedov II, Shestakova MV, Galstyan GR. Prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Sakharnyy diabet. 2016;19(2):104–112 (In Russ.)] doi: 10.14341/DM2004116-17
  25. Duan X, Liu J, Mu Y, Liu T, Chen Y, Yu R, et al. A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates. Medicine (Baltimore). 2020;99(9):e19303. doi: 10.1097/MD.0000000000019303
  26. Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014–1024. doi: 10.1016/j.jaad.2013.06.053
  27. Xu T, Zhang YH. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol. 2012;167(6):1345–1350. doi: 10.1111/bjd.12002
  28. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062. doi: 10.1161/JAHA.113.000062
  29. Raaby L, Ahlehoff O, de Thurah A. Psoriasis and cardiovascular events: updating the evidence. Arch Dermatol Res. 2017;309(3):225–228. doi: 10.1007/s00403-016-1712-1
  30. Ungprasert P, Srivali N, Kittanamongkolchai W. Psoriasis and risk of incident atrial fibrillation: A systematic review and meta-analysis. Indian J Dermatol Venereol Leprol. 2016;82(5):489–497. doi: 10.4103/0378-6323.186480
  31. Upala S, Shahnawaz A, Sanguankeo A. Psoriasis increases risk of new-onset atrial fibrillation: a systematic review and meta-analysis of prospective observational studies. J Dermatolog Treat. 2017;28(5):406–410. doi: 10.1080/09546634.2016.1255703
  32. Mamizadeh M, Tardeh Z, Azami M. The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(2):1405–1412. doi: 10.1016/j.dsx.2019.01.009
  33. Choudhary S, Pradhan D, Pandey A, Khan MK, Lall R, Ramesh V, et al. The Association of Metabolic Syndrome and Psoriasis: A Systematic Review and Meta-Analysis of Observational Study. Endocr Metab Immune Disord Drug Targets. 2020;20(5):703–717. doi: 10.2174/1871530319666191008170409
  34. Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017;77(4):657–666.e8. doi: 10.1016/j.jaad.2017.04.1133
  35. Budu-Aggrey A, Brumpton B, Tyrrell J, Watkins S, Modalsli EH, Celis-Morales C, et al. Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. PLoS Med. 2019;16(1):e1002739. doi: 10.1371/journal.pmed.1002739
  36. Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33(12):1163–1178. doi: 10.1007/s10654-018-0366-z
  37. Candia R, Ruiz A, Torres-Robles R, Chávez-Tapia N, Méndez-Sánchez N, Arrese M. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29(4):656–662. doi: 10.1111/jdv.12847
  38. Fu Y, Lee CH, Chi CC. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018;154(12):1417–1423. doi: 10.1001/jamadermatol.2018.3631
  39. Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. J Crohns Colitis. 2020;14(3):351–360. doi: 10.1093/ecco-jcc/jjz152
  40. Ungprasert P, Srivali N, Thongprayoon C. Association between psoriasis and chronic obstructive pulmonary disease: A systematic review and meta-analysis. J Dermatolog Treat. 2016;27(4):316–321. doi: 10.3109/09546634.2015.1107180
  41. Li X, Kong L, Li F, Chen C, Xu R, Wang H, et al. Association between Psoriasis and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. PLoS One. 2015;10(12):e0145221. doi: 10.1371/journal.pone.0145221
  42. Ungprasert P, Raksasuk S. Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50(7):1277–1283. doi: 10.1007/s11255-018-1868-z
  43. Puig L. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int J Mol Sci. 2017;19(1):58. doi: 10.3390/ijms19010058
  44. Boehncke WH. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Front Immunol. 2018;9:579. doi: 10.3389/fimmu.2018.00579
  45. Бакулев А.Л. Эволюция представлений о псориазе и терапевтических подходах по ведению пациентов. BCD-085 — первый отечественный генно-инженерный биологический препарат для лечения больных псориазом. Вестник дерматологии и венерологии. 2018;94(5):26–32. [Bakulev AL. Jevoljucija predstavlenij o psoriaze i terapevticheskih podhodah po vedeniju pacientov. BCD-085 — pervyj otechestvennyj genno-inzhenernyj biologicheskij preparat dlja lechenija bol'nyh psoriazom. Vestnik dermatologii i venerologii. 2018;94(5):26–32 (In Russ.)] doi: 10.25208/0042-4609-2018-94-5-26-32
  46. Egeberg A, Gisondi P, Carrascosa JM, Warren RB, Mrowietz U. The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. J Eur Acad Dermatol Venereol. 2020;34(8):1695–1706. doi: 10.1111/jdv.16273
  47. Egeberg A. Psoriasis and comorbidities. Epidemiological studies. Dan Med J. 2016;63(2):B5201.
  48. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi: 10.1016/j.jaad.2016.07.064
  49. Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018;79(2):345–352. doi: 10.1016/j.jaad.2018.02.040
  50. Gliklich R, Dreyer N, Leavy M, eds. Registries for Evaluating Patient Outcomes: A User’s Guide. Third edition. Two volumes. (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No. 290 2005 00351 TO7.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD:Agency for Healthcare Research and Quality. April 2014. http://www.effectivehealthcare.ahrq.gov/registriesguide-3.cfm
  51. Brown ML, Gersh BJ, Holmes DR, Bailey KR and Sundt III TM. From randomized trials to registry studies: translating data into clinical information. Nat Clin Pract Cardiovasc Med. 2008;5(10):613–620. doi: 10.1038/ncpcardio1307
  52. Monti S, Grosso V, Todoerti M, Caporali R. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatology (Oxford). 2018;57(57 Suppl 7):vii54-vii58. doi: 10.1093/rheumatology/key109
  53. O’Leary CP, Cavender MA. Emerging opportunities to harness real world data: An introduction to data sources, concepts and applications. Diabetes Obes Metab.2020;22(Suppl.3):3–12. doi: 10.1111/dom.13948
  54. de la Torre Hernández JM, Edelman ER. From Nonclinical Research to Clinical Trials and Patient-registries: Challenges and Opportunities in Biomedical Research. Rev Esp Cardiol (Engl Ed). 2017;70(12):1121–1133. doi: 10.1016/j.rec.2017.07.008
  55. Egeberg A, Nast A. A critical eye on registry data in psoriasis. Br J Dermatol 2017;177:245–246. doi: 10.1111/bjd.15309

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Distribution of patients by the body surface area (BSA) at the time of inclusion in the psoriasis patient register (n = 2931)

Download (183KB)
Indexing metadata
3. Fig. 2. Distribution of patients with psoriasis by WHO body mass index classification (n = 3045)

Download (405KB)
Indexing metadata

Copyright (c) 2022 Kubanov A.A., Bogdanova E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».